Effect of low-dose factor VIII prophylaxis therapy on bone mineral density and 25(OH) vitamin D level in children with severe haemophilia A
- PMID: 31884718
- DOI: 10.1111/hae.13917
Effect of low-dose factor VIII prophylaxis therapy on bone mineral density and 25(OH) vitamin D level in children with severe haemophilia A
Abstract
Background: Decreased bone mineral density (BMD) is a significant morbidity in haemophilia. Vitamin D is important for the bone health of people with haemophilia. Regular factor VIII prophylaxis can prevent bleeding and arthropathy.
Aim: To determine the 25(OH) vitamin D level in severe haemophilia A patients and correlate it to their Hemophilia Joint Health Score (HJHS) and dual-energy X-ray absorptiometry (DEXA). We also compared the 25(OH) vitamin D and DEXA in haemophilia A and healthy children and in haemophilia A children on prophylaxis versus on-demand therapy.
Methods: Fifty severe haemophilia A patients were compared to 50 age-matched healthy boys. Patients were recruited from the Pediatric Hematology Clinic, Ain Shams University from May 2017 to April 2018. Full medical history was taken with emphasis on frequency of bleeding episodes, duration and amplitude of pain assessed by the pain score. Weight, height, body mass index and HJHS were assessed. 25(OH) vit-D3, calcium, phosphorus and alkaline phosphatase were measured. BMD was assessed using Lunar DEXA, paediatric software.
Results: People with haemophilia had significantly lower 25(OH) vit-D3 (P < .001) and DEXA z-score (P < .001) than controls. Seventy per cent of patients were on factor VIII prophylaxis twice weekly (15U/kg/dose). Significant difference was found regarding DEXA z-score (P = .012), 25(OH) vit-D3 (P = .033) and HJHS (P = .022) among patients on prophylaxis and on-demand therapy.
Conclusion: Severe haemophilia A patients showed significantly lower 25(OH) vit-D3 and DEXA than controls. Hence, vitamin D deficiency should be tested in all people with haemophilia for early diagnosis and treatment. Low-dose prophylaxis in severe haemophilia preserves BMD and increases vitamin D. Further studies are required to evaluate the effect of different prophylaxis protocols on BMD and haemophilic arthropathy.
Keywords: Factor VIII; bone mineral density; prophylaxis therapy; severe haemophilia A; vitamin D.
© 2019 John Wiley & Sons Ltd.
Similar articles
-
Tissue-inhibitors of metalloproteinase-1 and vascular-endothelial growth-factor in severe haemophilia A children on low dose prophylactic recombinant factor VIII: Relation to subclinical arthropathy.Haemophilia. 2020 Jul;26(4):607-614. doi: 10.1111/hae.14041. Epub 2020 May 23. Haemophilia. 2020. PMID: 32445517
-
Comparison of the efficacy and safety of 12-month low-dose factor VIII tertiary prophylaxis vs on-demand treatment in severe haemophilia A children.Haemophilia. 2019 Jul;25(4):633-639. doi: 10.1111/hae.13770. Epub 2019 May 2. Haemophilia. 2019. PMID: 31044491 Clinical Trial.
-
Long-term prophylaxis in severe haemophilia seems to preserve bone mineral density.Haemophilia. 2009 Jan;15(1):261-6. doi: 10.1111/j.1365-2516.2008.01912.x. Epub 2008 Nov 3. Haemophilia. 2009. PMID: 19149852
-
Optimizing factor prophylaxis for the haemophilia population: where do we stand?Haemophilia. 2004 Oct;10 Suppl 4:97-104. doi: 10.1111/j.1365-2516.2004.00998.x. Haemophilia. 2004. PMID: 15479380 Review.
-
Low-dose prophylaxis and its impact on the health of haemophilia patients.Vox Sang. 2022 Jul;117(7):900-912. doi: 10.1111/vox.13278. Epub 2022 Apr 18. Vox Sang. 2022. PMID: 35437811 Review.
Cited by
-
Simoctocog alfa (Nuwiq®) in children: early steps in life's journey for people with severe hemophilia A.Ther Adv Hematol. 2024 May 9;15:20406207241245511. doi: 10.1177/20406207241245511. eCollection 2024. Ther Adv Hematol. 2024. PMID: 38737006 Free PMC article. Review.
-
Design of an international investigator-initiated study on MOdern Treatment of Inhibitor-positiVe pATiEnts with haemophilia A (MOTIVATE).Ther Adv Hematol. 2021 Sep 23;12:20406207211032452. doi: 10.1177/20406207211032452. eCollection 2021. Ther Adv Hematol. 2021. PMID: 34589194 Free PMC article.
-
PHILEOS (haemoPHILia and ostEoporOSis) Study: protocol of a multicentre prospective case-control study.BMJ Open. 2021 Jan 13;11(1):e042283. doi: 10.1136/bmjopen-2020-042283. BMJ Open. 2021. PMID: 33441362 Free PMC article.
-
Haemophilia and Fragility Fractures: From Pathogenesis to Multidisciplinary Approach.Int J Mol Sci. 2023 May 28;24(11):9395. doi: 10.3390/ijms24119395. Int J Mol Sci. 2023. PMID: 37298347 Free PMC article. Review.
-
A Delphi Consensus Approach for Difficult-to-Treat Patients with Severe Hemophilia A without Inhibitors.J Blood Med. 2021 Oct 21;12:913-928. doi: 10.2147/JBM.S334852. eCollection 2021. J Blood Med. 2021. PMID: 34707422 Free PMC article.
References
REFERENCES
-
- Rodriguez-Merchan EC. Musculoskeletal complications of hemophilia. HSS J. 2010;6(1):37-42.
-
- Albayrak C, Albayrak D. Vitamin D levels in children with severe hemophilia A. Blood Coagul Fibrinolysis. 2015;26(3):285-289.
-
- Wren TA, Kalkwarf HJ, Zemel BS, et al. Longitudinal tracking of dual-energy X-ray absorptiometry bone measures over 6 years in children and adolescents: persistence of low bone mass to maturity. J Pediatr. 2014;164:1280-1285.
-
- Alioglu B, Selver B, Ozsoy H, et al. Evaluation of bone mineral density in Turkish children with severe haemophilia A: Ankara hospital experience. Haemophilia. 2012;18:69-74.
-
- Franco P. Osteoporosis in haemophilic patient, rehabilitative aspects. Clin Cases Miner Bone Metab. 2012;9(2):96-99.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous